{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:29Z","timestamp":1787878229444,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100018528","name":"Korean Neurological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018528","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:20:06Z","timestamp":1708503606000},"page":"306-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study"],"prefix":"10.1016","volume":"10","author":[{"given":"Jee Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Beom","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.02.002_b0005","unstructured":"Harding CK, Lapitan MC, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms (LUTS). 2021. uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Non-Neurogenic-Female-LUTS-2021.pdf."},{"key":"10.1016\/j.euf.2024.02.002_b0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0015","unstructured":"Rahanama'i S, editor. ICS standardisation committee terminology discussions: overactive bladder. http:\/\/www.ics.org\/committees\/standardisation\/terminologydiscussions\/overactivebladder."},{"key":"10.1016\/j.euf.2024.02.002_b0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0025","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.02.002_b0030","doi-asserted-by":"crossref","first-page":"e2317","DOI":"10.1097\/MD.0000000000023171","article-title":"Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder","volume":"100","author":"Su","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.euf.2024.02.002_b0035","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0040","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur Urol."},{"key":"10.1016\/j.euf.2024.02.002_b0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jalz.2012.02.005","article-title":"Chronic anticholinergic use and the aging brain","volume":"9","author":"Cai","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.euf.2024.02.002_b0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Nondegenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.02.002_b0055","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euf.2024.02.002_b0060","article-title":"Anticholinergic drugs and risk of dementia: case control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.02.002_b0065","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.euf.2021.10.009","article-title":"Receipt of overactive bladder drugs and incident dementia: a population-based case-control study","volume":"8","author":"Matta","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.02.002_b0070","doi-asserted-by":"crossref","first-page":"103885","DOI":"10.1016\/j.archger.2019.05.010","article-title":"A review of published anticholinergic scales and measures and their applicability in database analyses","volume":"87","author":"Lozano-Ortega","year":"2020","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.euf.2024.02.002_b0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12877-019-1401-y","article-title":"Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.euf.2024.02.002_b0080","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41598-021-84229-2","article-title":"Use of bladder antimuscarinics is associated with an increased risk of dementia: a retrospective population-based case-control study","volume":"11","author":"Harnod","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2024.02.002_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.02.002_b0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","article-title":"Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder","volume":"29","author":"Chancellor","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euf.2024.02.002_b0095","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/JU.0000000000002804","article-title":"Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French National Medical-Administrative Database","volume":"208","author":"Malcher","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13195-021-00842-3","article-title":"Repurposing beta-3 adrenergic receptor agonists for Alzheimer\u2019s disease: beneficial effects in a mouse model","volume":"13","author":"Tournissac","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.euf.2024.02.002_b0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u2265 65 yr with overactive bladder wet: a phase IV, double-blind, randomized, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.02.002_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-020-01003-z","article-title":"Are beta 3 adrenergic agonists now the preferred pharmacologic management of overactive bladder?","volume":"21","author":"Fogaing","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euf.2024.02.002_b0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0125","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.02.002_b0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomized double-blind multicentre Phase 3b study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0135","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bju.13068","article-title":"Safety and efficacy of mirabegron as \u2018add-on\u2019 therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)","volume":"116","author":"Yamaguchi","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.02.002_b0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2024.02.002_b0145","unstructured":"Norwegian Institute of Public Health. WHO Collaborating Centre for Drug Statistics and Methodology. https:\/\/www.fhi.no\/en\/hn\/drug\/who-collaborating-centre-for-drug-statistics-methodology\/."},{"key":"10.1016\/j.euf.2024.02.002_b0150","first-page":"e12290","article-title":"Association between anticholinergic burden and dementia in UK Biobank","volume":"8","author":"Mur","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.euf.2024.02.002_b0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cmet.2020.07.005","article-title":"Human brown adipocyte thermogenesis is driven by \u03b22-AR stimulation","volume":"32","author":"Blondin","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.euf.2024.02.002_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.euf.2024.02.002_b0165","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2147\/IJWH.S372597","article-title":"Mirabegron in the management of overactive bladder syndrome","volume":"14","author":"O\u2019Kane","year":"2022","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.euf.2024.02.002_b0170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0896-6273(02)00828-0","article-title":"Function and regulation of CREB family transcription factors in the nervous system","volume":"35","author":"Lonze","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.euf.2024.02.002_b0175","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jcb.26321","article-title":"cAMP\/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease","volume":"119","author":"Li","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.euf.2024.02.002_b0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1201\/9781482276664-32","article-title":"Beta adrenergic agonists","author":"Anderson","year":"2004","journal-title":"Encycl of Anim Sci"},{"key":"10.1016\/j.euf.2024.02.002_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.expneurol.2012.05.008","article-title":"Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-\u03b2 peptide via action at \u03b2-adrenoceptors and activation of cAMP\/PKA pathway in human THP-1 macrophages","volume":"236","author":"Yang","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.euf.2024.02.002_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.euf.2024.02.002_b0195","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bmj.315.7119.1363","article-title":"Oxybutynin and cognitive dysfunction","volume":"315","author":"Donnellan","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.02.002_b0200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.002_b0205","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pds.4267","article-title":"Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan","volume":"27","author":"Kao","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.euf.2024.02.002_b0210","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14740338.2019.1652269","article-title":"Cognitive and mood side effects of lower urinary tract medication","volume":"18","author":"Muderrisoglu","year":"2019","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:26:34Z","timestamp":1762622794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405456924000191"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.02.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}